Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: TSAVARIS
Liczba odnalezionych rekordów: 3



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku

1/3

Tytuł oryginału: Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients.
Autorzy: Tsavaris Nicolas, Kosmas Christos, Vadiaka Maria, Efremidis Michalis, Zinelis Andreas, Beldecos Dimitris, Sakelariou Dimitris, Koufos Christos, Stamatelos George
Źródło: Med. Sci. Monitor 2002: 8 (6) s.PI51-PI57, tab., bibliogr. 27 poz.
Sygnatura GBL: 313,278

Hasła klasyfikacyjne GBL:
  • toksykologia
  • kardiologia

    Typ dokumentu:
  • praca kliniczna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Although cardiotoxicity associated with 5-Fluorouracil (5-FU) administration is infrequent, there are case reports of acute coronary syndromes. We report on patients undergoing 5-FU chemotherapy who developed cardiac symptoms during its administration. In patients receiving 5-FU who experienced cardiac-related symptoms, ECG and serum cardiac enzyme determination were performed. If cardiotoxicity was detected, 5-FU infusion was interrupted, and the patients received sublingual nitrates and caradiac monitored in a coronary care unit for at least 72 hours. In cases of acute myocardial infarction, 5-FU was terminated Of 427 patients entering the study, 17 (4 p.c.) developed clinical symptoms and ECG abnormalities indicating 5-FU cardiotoxicity. Patients with continuous infusion (c.i.) of 5-FU had a higher incidence of cardiotoxicity (12/197, 6 p.c.) than the remaining (5/235, 2.1 p.c.) (p = 0.067), but more toxicity was enccountered in patients with c.i. of 5-fu + LV for 24 hours for 5 days than in patients with the same regimen of 5-FU without LV (p 0.027) or patients with short 5-FU + LV administration (p = 0.024). Seven of the 17 patients with 5-FU cardiotoxicity had an acute myocardial infarction, 4 developed ischemic changes, while 4 more patients had ECG abnormalities consistent with coronary vasospasm, of whom one subsequently died. The present study supports the toxic effect of 5-FU on myocardium which is largely schedule-dependent. Considerable vigilance is required when usnig this drug, and its toxic effect on the coronary endothelium and myocardium merit further investigation.


    2/3

    Tytuł oryginału: Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
    Autorzy: Kosmas Christos, Tsavaris Nicolas, Kalofonos Haralambos P.
    Źródło: Med. Sci. Monitor 2002: 8 (6) s.PI58-PI63, tab., bibliogr. 36 poz.
    Sygnatura GBL: 313,278

    Hasła klasyfikacyjne GBL:
  • pulmonologia
  • onkologia

    Typ dokumentu:
  • praca kliniczna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Docetaxel has been the only single agent with proven activity and documented survival benefit in the second-line treatment of advanced/refractory non-small cell lung cancer (NSCLC). Combinations of docetaxel with other active agents in this setting, such as gemcitabine, besides their popularity as front-line treatment, are currently being explored in an attempt to improve the results over single-agent docetaxel in relapsed/refractory NSCLC. Given the established activity of single-agent decetaxel in two recent large randomized phase III trials against best supportive care or versus single-agent Vinorelbine or Ifosfamide in patients with platinum pretreated NSCLC, and the proven activity of single-agent gemcitabine in this setting, combination regimens employing these two agents in various doses and schedules have recently been initiated. Adequately designed phase II studies using standard criteria of efficacy and safety, which peer-review based publication, were selected from the literature. The gemcitabine/docetaxel combination regimens employing these two agents in various doses and schedules have recently been initiated. Adequately designed phase II studies using standard criteria of efficacy and safety, with peer-review based publication, were selected from the literature. The gemcitabine/docetaxel combination in various schedules with or without G-CSF support as salvage therapy of NSCLC pre-treated with platinum + paclitaxel - based regimens has been evaluated in four recently published phase II clinical studies, and has been shown to represent a tolerable and active regimen in this setting, yielding a 10 - 33 p.c. response rate, improvement of disease-related symptoms, and meaningful median and 1-year survival figures in the...


    3/3

    Tytuł oryginału: Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer.
    Autorzy: Tsavaris Nicolas, Kosmas Christos, Gennatas Kostas, Vadiaka Maria, Paliaros Platon, Dimitrakopoulos Antonis, Diamantis Theodoros, Tsipras Heraklis, Papastratis George
    Źródło: Med. Sci. Monitor 2002: 8 (9) s.PI65-PI69, bibliogr. 33 poz.
    Sygnatura GBL: 313,278

    Hasła klasyfikacyjne GBL:
  • onkologia
  • toksykologia
  • farmacja
  • gastroenterologia

    Typ dokumentu:
  • tytuł obcojęzyczny
  • praca kliniczna

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Background: We evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU. Material/Methods: Etoposide was administered at 3 different dose levels (DL), in 3 groups of patients (Total - 60); DL-I - etoposide 80 mg/mý, 45 min i.v. infusion, DL-II - etoposide 120 mg/mý, and DL-III - etoposide 180 mg/mý. In all three levels etoposide was followed by LV 100 mg/mý i.v., 1-hour infusion, and 5-FU 500 mg/mý i.v. bolus. Treatment was adminsitered until disease progression or unacceptable toxicity. Results: No patients responded at DL-I, while 2 patients at DL-II and 3 at DL-III had a partial response (PR) (P 0.1). Two patients had stable disease (SD) at DL-I, 8 at DL-II, and 9 at DL-III (P 0.01). More patients progressed at DL-I (n = 19) compared to DL-II (n - 10) and DL-III (n = 8) (p 0.0007). The time to progression was 17, 15, and 14 weeks, respectively, for DL-I, -II, and -III (P = 0.9). Median survival was 30, 30, and 32.5 weeks, respectively, for DL-I, -II, and -III (P = 0.27). Toxicity was mainly neutropenia, diarrhea and mucositis at all DLs, significantly more intense in DL-III. No difference was noticed in responses between DL-II and DL-III, but toxicity in DL-III was more severe. Conclusions: The combination of etoposide with LV+5-FU has limited activity when adminsitered after failure of weekly LV+5-FU in patients with ACC.

    stosując format: